DrugPatentWatch Database Preview
Details for Patent: 7,910,132
Which drugs does patent 7,910,132 protect, and when does it expire?
Patent 7,910,132 protects ABSTRAL and is included in one NDA.
This patent has seventy-two patent family members in twenty-eight countries.
Summary for Patent: 7,910,132
| Title: | Pharmaceutical composition for the treatment of acute disorders |
| Abstract: | A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders. |
| Inventor(s): | Pettersson; Anders (Kode, SE), Nystrom; Christer (Lidingo, SE) |
| Assignee: | Orexo AB (Uppsala, SE) |
| Application Number: | 11/544,660 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 7,910,132
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sentynl Theraps Inc | ABSTRAL | fentanyl citrate | TABLET;SUBLINGUAL | 022510-001 | Jan 7, 2011 | AB | RX | Yes | No | Start Trial | Start Trial | Y | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | Start Trial | ||
| Sentynl Theraps Inc | ABSTRAL | fentanyl citrate | TABLET;SUBLINGUAL | 022510-002 | Jan 7, 2011 | AB | RX | Yes | No | Start Trial | Start Trial | Y | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | Start Trial | ||
| Sentynl Theraps Inc | ABSTRAL | fentanyl citrate | TABLET;SUBLINGUAL | 022510-003 | Jan 7, 2011 | AB | RX | Yes | No | Start Trial | Start Trial | Y | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | Start Trial | ||
| Sentynl Theraps Inc | ABSTRAL | fentanyl citrate | TABLET;SUBLINGUAL | 022510-004 | Jan 7, 2011 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | Start Trial | ||
| Sentynl Theraps Inc | ABSTRAL | fentanyl citrate | TABLET;SUBLINGUAL | 022510-005 | Jan 7, 2011 | AB | RX | Yes | No | Start Trial | Start Trial | Y | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | Start Trial | ||
| Sentynl Theraps Inc | ABSTRAL | fentanyl citrate | TABLET;SUBLINGUAL | 022510-006 | Jan 7, 2011 | AB | RX | Yes | No | Start Trial | Start Trial | Y | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,910,132
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Sweden | 9803240 | Sep 24, 1998 |
International Family Members for US Patent 7,910,132
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 365540 | Start Trial | |||
| Australia | 6492799 | Start Trial | |||
| Australia | 764346 | Start Trial | |||
| Bulgaria | 105379 | Start Trial | |||
| Bulgaria | 65502 | Start Trial | |||
| Brazil | 9913945 | Start Trial | |||
| Canada | 2345121 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
